Ignite Creation Date:
2024-05-06 @ 4:06 PM
Last Modification Date:
2024-10-26 @ 2:04 PM
Study NCT ID:
NCT04874844
Status:
UNKNOWN
Last Update Posted:
2021-05-10
First Post:
2021-04-12
Brief Title:
JY025 is a First-line Treatment for EGFR Mutated NSCLC Phase II and III Clinical Trials of Efficacy and Safety
Sponsor:
Beijing Dongfang Biotech Co Ltd
Organization:
Beijing Dongfang Biotech Co Ltd
Organization Data
Organization:
Beijing Dongfang Biotech Co Ltd
Class:
INDUSTRY
Study ID:
DFBT-JY025-NSCLC-2020-30I
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Beijing Dongfang Biotech Co Ltd
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Chinese Academy of Medical Sciences | OTHER |